Ascendis Pharma A/S Announces Updated Time for April 3 Conference Call to Review ENDO 2017 Data

COPENHAGEN, Denmark, March 31, 2017 /PRNewswire/ -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases, today announced that the company has updated the time for its conference call and webcast on Monday, April 3 during ENDO 2017, the annual meeting of the Endocrine Society in Orlando, Florida.

The conference call and webcast will now be held at 8:00 a.m. Eastern Time (ET) to discuss new data regarding Ascendis Pharma's three rare disease pipeline candidates (TransCon Growth Hormone, TransCon PTH and TransCon CNP).

Details for the conference call and webcast include:

Ascendis is presenting eight posters, including two late-breakers, during the ENDO 2017 conference. Copies of all posters will be made available on the Selected Publications page in the Pipeline section of the company's website to coincide with the presentations at ENDO. A detailed schedule of the poster presentations can be found on the company's website at: http://phx.corporate-ir.net/phoenix.zhtml?c=242088&p=irol-newsArticle&ID=2250378.

A live webcast of the conference call will be available on the Investors & News section of the Ascendis Pharma website at www.ascendispharma.com. A webcast replay will also be available for 30 days.

About Ascendis Pharma A/S

Ascendis Pharma is applying the TransCon technology platform to build a leading rare disease commercial company. The company utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases by improving clinically validated parent drugs and creating therapies with potential for best-in-class efficacy, safety and/or convenience.

Ascendis Pharma has a wholly-owned pipeline of rare disease endocrinology programs, including once-weekly TransCon Growth Hormone, which is currently being evaluated in the Phase 3 heiGHt Trial for children with growth hormone deficiency (GHD), TransCon PTH, a long-acting prodrug of parathyroid hormone for hypoparathyroidism, and TransCon CNP, a long-acting prodrug of C-Type Natriuretic Peptide for achondroplasia. Additionally, Ascendis Pharma has multi-product collaborations with Sanofi in diabetes and Genentech in the field of ophthalmology.

For more information, please visit www.ascendispharma.com.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) our ability to apply the TransCon technology platform to build a leading rare disease commercial company and (ii) our expectations regarding our ability to create therapies with potential for best-in-class efficacy, safety and/or convenience. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that we make, including the following: unforeseen safety or efficacy results in our TransCon Growth Hormone, TransCon PTH and TransCon CNP or other development programs; unforeseen expenses related to the development of TransCon Growth Hormone, TransCon PTH and TransCon CNP or other development programs, general and administrative expenses, other research and development expenses and our business generally; delays in the development of TransCon Growth Hormone, TransCon PTH and TransCon CNP or other development programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; dependence on third party manufacturers to supply study drug for planned clinical studies; and our ability to obtain additional funding, if needed, to support our business activities. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to our business in general, see our current and future reports filed with, or submitted to, the U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F for the year ended December 31, 2016, which we filed with the SEC on March 22, 2017. Forward-looking statements do not reflect the potential impact of any future in-licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments we may enter into or make. We do not assume any obligation to update any forward-looking statements, except as required by law.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ascendis-pharma-as-announces-updated-time-for-april-3-conference-call-to-review-endo-2017-data-300432502.html

SOURCE Ascendis Pharma A/S